GSK Acquires Rapt Therapeutics For $2.2 Billion
In its first transaction of the year, GSK Plc, announced that it acquired Rapt Therapeutics, Inc. for $58 per share. That price equates to an aggregate equity value of $2.2 billion, according to GSK, which added that the upfront investment net of cash acquired comes to $1.9 billion. Net of cash acquired, GSK’s estimated upfront investment is $1.9 billion. Based in South San Francisco, California, RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients. It develops novel therapies that are designed to modulate the critical immune responses underlying these diseases. According to a... Read More »
Sanofi Acquires Dynavax Technologies for $2.2 Billion
Sanofi is rounding out 2025 with a multi-billion-dollar transaction. On December 24, the company announced that it entered into an agreement to acquire Dynavax Technologies Corporation, based in Emeryville, California. Under the terms of the agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Dynavax Technologies is a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate (Z-1018). According to its most recent annual SEC filing, Dynavax reported approximately $277.2 million... Read More »
Innova Therapeutics Advances Novel Cancer Treatment With Enci Therapeutics Deal
Innova Therapeutics has completed its purchase of South Carolina-based biotechnology company Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway. SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes, including overall survival, making it an important therapeutic target. As an SFRP2 antagonist, IVT-8086 selectively blocks the non-canonical Wnt/Ca2+ signaling... Read More »
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion
Johnson & Johnson (J&J) announced on November 17 that it entered into an agreement to acquire Halda Therapeutics. The purchase price is $3.05 billion. Founded by Yale scientist, Professor Craig Crews, Halda Therapeutics is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its business lines include... Read More »
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Limited
JSR Life Sciences LLC, a global leader in life sciences materials and services, announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited. The deal will enable Crown Bioscience to operate as a standalone entity under Adicon’s ownership. The transaction, subject to customary closing conditions, is expected to close in 2026. Financial terms were not disclosed. Crown Bioscience is a contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. The company has a comprehensive portfolio of translational oncology services, including its patient-derived xenograft models, tumor... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
